HGV and TTV - New hepatitis viruses

Aim. To examine clinical, immunological and morphological features of HGV- and TTV-infections in patients with chronic hepatic diseases (CHD) and asse ss efficiency of treatment of HGV-seropositive patients. Material and methods. 202 patients with CHD were examined for markets of HB V-, HCY-, HGV- and TTV-infections. Some patients were subjected to puncture biopsy of the liver: Efficiency of interferon-alpha treatment of HGV and H BV/HCV coinfection,vas studied. Results. HGV RNA and TTV DNA were detected in 19.8 and 11.8% of cases, resp ectively. Biochemical indices in patients with HGV and TTV monoinfections s ignificantly differed from those in the control group while morphological c hanges in most of them corresponded to those with hepatitis. INF-alpha was given to 7 patients with HCV+HBV/HCV infections. A response was achieved in 3 months in 2 of them. Conclusion. The role of HGV and TTV in hepatic diseases pathology is still unclear. Further studies on detection and examination of patients infected with G and TT vir uses are necessary. When choosing therapy, the presence o f HGV RNA and TTV DNA in blood serum, virus genome in hepatocytes and histo logical changes in hepatic tissue should be considered.